Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Structure Therapeutics Inc. - American Depositary Shares (NQ:GPCR)

46.92 +2.98 (+6.78%)
Streaming Delayed Price Updated: 1:31 PM EDT, Mar 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 755,581
Open 44.92
Bid (Size) 46.72 (100)
Ask (Size) 46.96 (100)
Prev. Close 43.94
Today's Range 44.45 - 47.77
52wk Range 13.22 - 94.90
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Main Street’s Revenge: The Great Rotation of 2026 Rewrites Market History
The financial landscape of 2026 has been defined by a singular, tectonic shift that few predicted would be this absolute: the definitive end of the mega-cap tech era and the roaring resurgence of the... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
The Great Rotation: Small-Caps Seize Market Leadership in Historic 2026 Breakout
The financial landscape has undergone a tectonic shift in the opening months of 2026, as the long-dormant Russell 2000 index has surged to record highs, marking what many analysts believe is the... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property

Performance

YTD
-31.1%
-31.1%
1 Month
-25.4%
-25.4%
3 Month
-30.4%
-30.4%
6 Month
+85.5%
+85.5%
1 Year
+171.1%
+171.1%

More News

Read More
VKTX, TERN, GPCR Shares Rally As Novo Nordisk Sounds Willingness Towards Portfolio-Expansion Deals ↗
Via Stocktwits
News headline image
The Great Rotation: Russell 2000 Outshines Mega-Caps as Domestic Small-Caps Take the Reins in 2026
Via MarketMinute
Topics Artificial Intelligence Economy World Trade
News headline image
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges ↗
Via The Motley Fool
News headline image
3 Companies at the Forefront of the GLP-1 Pill Wars ↗
Via MarketBeat
News headline image
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
From Structure Therapeutics Inc.
Via GlobeNewswire
News headline image
Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The Valuation Reset: A Deep-Dive into Novo Nordisk (NVO) in 2026
Via Finterra
Topics Economy Intellectual Property
News headline image
Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
News headline image
Structure Therapeutics Stock Soars Over 200% as One Fund Adds to a $242 Million Position ↗
Via The Motley Fool
News headline image
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The Trillion-Dollar Pharmaceutical Giant: Eli Lilly Makes History as Weight-Loss Revolution Drives Unprecedented Growth
Via MarketMinute
Topics Earnings Economy
News headline image
Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake ↗
Via The Motley Fool
News headline image
Eli Lilly Projects Record $80B-$83B Revenue for 2026 as Metabolic Franchise Decouples from Competition
Via MarketMinute
Topics Earnings Economy
News headline image
This Healthcare Company Believes Its GLP-1 Pill Could Be "Next in Line" After Novo Nordisk and Eli Lilly. Its Valuation Is a Fraction of Theirs. ↗
Via The Motley Fool
News headline image
A 10% Owner Of Structure Therapeutics Shed Shares ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Can This Stock Double Again in 2026? ↗
Via The Motley Fool
News headline image
The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Hims & Hers Enters 2026 On Solid Ground — Stock Rises Even After Novo Nordisk Leaves It Off Wegovy Partner List ↗
Via Stocktwits
News headline image
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
The Case for Small-Cap Diversification: Why Investors are Looking Beyond Mega-Cap Tech
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
Novo Nordisk Breaks the Mold: Oral Obesity Breakthrough Sends Shares to New Heights as Pharma Landscape Shifts
Via MarketMinute
Topics Economy
News headline image
The Great Rotation: Small-Caps Seize the Spotlight as Mega-Cap Fatigue Sets In
Via MarketMinute
Topics Economy

Frequently Asked Questions

Is Structure Therapeutics Inc. - American Depositary Shares publicly traded?
Yes, Structure Therapeutics Inc. - American Depositary Shares is publicly traded.
What exchange does Structure Therapeutics Inc. - American Depositary Shares trade on?
Structure Therapeutics Inc. - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Structure Therapeutics Inc. - American Depositary Shares?
The ticker symbol for Structure Therapeutics Inc. - American Depositary Shares is GPCR on the Nasdaq Stock Market
What is the current price of Structure Therapeutics Inc. - American Depositary Shares?
The current price of Structure Therapeutics Inc. - American Depositary Shares is 46.92
When was Structure Therapeutics Inc. - American Depositary Shares last traded?
The last trade of Structure Therapeutics Inc. - American Depositary Shares was at 03/31/26 01:31 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.